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Background: Long pentraxin 3 (PTX3) is a component of the pentraxin superfamily and a potential marker of
vascular damage and inflammation, associated with negative outcome in patients with acute coronary syndromes
(ACS). Obesity is a risk factor for cardiovascular disease and PTX3 production is reported in abdominal adipose
tissue. Low PTX3 is however reported in the obese population, and obesity per se may be associated with less
negative ACS outcome.
Methods: We investigated the potential impact of obesity and high waist circumference (reflecting abdominal
fat accumulation) on plasma PTX3 concentration in ACS patients (n = 72, 20 obese) compared to age-, sex- and
BMI-matched non-ACS individuals.
Results: Both obese and non-obese ACS patients had higher PTX3 than matched non-ACS counterparts, but PTX3
was lower in obese than non-obese individuals in both groups (all P < 0.05). PTX3 was also lower in ACS subjects
with high than in those with normal waist circumference (WC). Plasma PTX3 was accordingly associated negatively
with BMI and WC, independently of age and plasma creatinine. No associations were observed between PTX3 and
plasma insulin, glucose or the short pentraxin and validated inflammation marker C-reactive protein, that was higher
in ACS than in non-ACS individuals independently of BMI or WC.
Conclusions: Obesity is associated with low circulating PTX3 in ACS. This association is also observed in the
presence of abdominal fat accumulation as reflected by elevated waist circumference. Low PTX3 is a novel
potential modulator of tissue damage and outcome in obese ACS patients.
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The pentraxin superfamily includes short and long com-
ponents [1,2]. C-reactive protein is a liver-synthesized
short pentraxin and a strongly validated marker of sys-
temic inflammation [1-3]. Long pentraxins are however
synthesized by various cell types and may differentially
modulate the inflammatory response under different
clinical conditions [1-3]. In particular, long pentraxin 3
(PTX3) may be secreted by adipocytes under pro-
inflammatory stimuli and it has been proposed as a* Correspondence: barazzon@units.it
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stated.clinical marker of vascular damage [1,2]. Plasma PTX3
was accordingly reported to be elevated in patients with
arterial stiffness [4] and subclinical [5] or unstable ath-
erosclerotic lesions [6], and high circulating PTX3 is ob-
served in acute coronary syndromes (ACS) [7,8]. In ACS
patients, higher PTX3 was also remarkably associated
with negative outcome in terms of subsequent events
and overall survival [9,10]. Despite its clinical relevance,
factors modulating circulating PTX3 in ACS remain
however incompletely defined.
Obesity is an independent risk factor for coronary ar-
tery disease and ACS, but obesity per se has been para-
doxically associated with improved prognosis in ACS
patients [11,12]. In the general population [4,13] and inral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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and insulin resistance or metabolic syndrome [16-19],
low plasma PTX3 was found in most reports in obese
individuals and in subjects with high waist circumfer-
ence, despite high PTX3 expression in abdominal fat
[20,21]. The potential interactions between obesity, ab-
dominal fat accumulation and ACS in modulating
plasma PTX3 remain to be defined. In the current study
we therefore investigated the impact of obesity and waist
circumference on plasma PTX3 in non-obese and obese
ACS patients and in sex-, age and BMI-matched non-
ACS control subjects. We hypothesized that obesity has
a negative impact on circulating PTX3 in ACS, and that
similar interactions are also observed between PTX3
and high waist circumference, a surrogate marker of
abdominal fat accumulation. Finally, we tested the
hypothesis that changes in PTX3 are unrelated to those
of the short pentraxin and inflammation marker CRP in
ACS patients.
Methods and procedures
Subjects and experimental protocol
The study conforms to the principles outlined in the
Declaration of Helsinki and was approved by the institu-
tional Ethics Committee. All patients were given detailed
information on the study aims and risks and they gave
written consent before enrolled. In all participants, clin-
ical history and complete physical examination including
measurements of blood pressure, body mass index
(BMI) and waist circumference were collected. Obesity
was defined as BMI > 30 kg/m2, while high waist cir-
cumference was defined based on Adult Treatment
Panel III diagnostic criteria for metabolic syndrome
(>102 or 88 cm for male and female subjects, respect-
ively). Diagnosis of hypertension was based on blood
pressure measurement (>135/85 mmHg) or antihyper-
tensive medications; diagnosis of dyslipidemia was based
on plasma triglycerides (>150 mg/dl) and HDL choles-
terol (<50 or 40 mg/dl for females and males respect-
ively) or triglyceride-lowering medications; diagnosis of
type 2 diabetes was based on HbA1c >6.5% or antidia-
betic medications. Exclusion criteria were clinical or
laboratory evidence of liver failure or disease, renal fail-
ure (plasma creatinine above 1,5 mg/dl), cancer, chronic
autoimmune and thyroid disease. Females taking hormo-
nal estrogen therapy were also excluded from the study.
No subject in either group had history or clinical or
laboratory signs of systemic inflammatory disease.
ACS
72 consecutive patients with acute coronary syndrome
(50 non-obese, 22 obese) were recruited in Coronary
Care Unit from the Cardiovascular Department of the
Azienda Ospedaliero-Universitaria “Ospedali Riuniti” inTrieste. ACS was diagnosed based on WHO criteria in
the presence of two of the following criteria: ischemic
chest pain, serial ECG modifications, troponin I eleva-
tion with subsequent reduction. For all patients, one
overnight fasted blood sample was collected within
24 hours of admission. No differences in timing of sam-
ple collection occurred between non-obese and obese
patients. After separation, plasma was stored at −80 C
until biochemical and hormonal measurements were
performed.
Non-ACS
52 control subjects with no clinical history of coronary
artery disease based on detailed history and clinical
examination were also studied (33 non-obese, 19 obese).
These subjects were matched to the ACS groups for age,
sex, BMI, waist circumference. Overnight-fasted blood
samples were collected also for control subjects. Part of
the study results in a smaller study population, pertain-
ing to the associations between obesity, ACS, insulin
resistance and adipose tissue hormones have been
reported elsewhere [22].
Plasma analyses
Plasma glucose, HDL cholesterol and plasma triglycer-
ides were measured using standard methods. Plasma
insulin was measured by ELISA (Insulin Human Ultra-
sensitive ELISA; DRG Instruments, Marburg, Germany).
Insulin sensitivity was assessed by the validated HOMA
index using the following formula: HOMA= (FPG*FPI)/
22.5, where FPG and FPI are fasting plasma glucose
(mmol) and fasting plasma insulin (μU/ml) respectively
[20]. Plasma pentraxin-3 (PTX3) (Human Pentraxin3/
TSG-14ELISA System Perseus Proteomics Inc., Tokyo,
Japan) and C-reactive protein (CRP) (High sensitivity
c-reactive protein, Diagnostics Biochem Canada Inc
London, Ontario, Canada) were measured using com-
mercially available ELISA kit.
Statistical analysis
The StatView software (SAS Institute, Cary, NC, USA)
was used for statistical analyses. Normality Tests were
run to assess data distribution. Comparisons between
ACS patients and non-ACS control subjects were made
by unpaired Student’s t-test or Wilcoxon test for non-
parametric analyses in variables with non-normal
distribution (PTX3, HOMA-IR and CRP). To assess
differences between obese and non-obese ACS and
non-ACS patients, ANOVA or Kruskal-Wallis test for
non-parametric variables were used. Linear regression
analysis was used to determine associations between
PTX3 and different study variables that are potentially
involved in its regulation. Multiple regression analysis
was then used to investigate potential independent
Table 1 Clinical and biochemical profile
ACS Control
Gender (M/F) 60/12 44/8
Age (years) 63 ± 10 (42–85) 62 ± 5 (54–73)
BMI (kg/m2) 27.5 ± 3.8 (20.6-40.8) 27.9 ± 3.6 (21.6-40.5)




Type 2 Diabetes 16 12
Medications (%)
ACE-Inhib or ARB 48 42





SBP (mmHg) 131 ± 18 (95–175) 136 ± 16 (115–165)
DBP (mmHg) 72 ± 10 (55–100) 76 ± 6 (70–95)
Creat (mg/dl) 1.01 ± 0.28 (0.55-1.5) 0.92 ± 0.20 (0.60-1.4)
Tg (mg/dl) 126 ± 65 (44–585) 146 ± 35 (110–289)
T-Chol (mg/dl) 191 ± 42 (81–316) 215 ± 41 (127–261)
HDL-Chol (mg/dl) 45 ± 8 (24–85) 48 ± 8 (32–65)
Glucose (mg/dl) 121 ± 26 (60–221) 114 ± 10 (86–131)
Insulin (μU/ml) 4.6 ± 2.4 (1.5-12) 5.4 ± 3.3 (1.2-15.4)
HOMA-IR 1.45 ± 0.95 (0.3-4.8) 1.50 ± 0.96 (0.5-3.8)
CK (mU/ml) 124 (8.4-888) -
Troponin (ng/ml) 14.6 (0.5-326) -
CRP (mg/dl) 2 (0.2-15) 0.2 (0.02-3.1)*
PTX3 (ng/ml) 5.7 (1.8-29.3) 2.7 (1.2-5.6)*
Gender, age, BMI, waist circumference (WC), disease prevalence, chronic
medications (treatment before event for ACS); ACE-Inhib: Angiotensin Convert-
ing Enzyme-Inhibitors; ARB: Angiotensin Receptor Blockers; ASA: Acetylsalicylic
Acid; systolic (SBP) and diastolic (DBP) blood pressure, plasma creatinine
(creat), triglycerides (Tg), HDL cholesterol (HDL-Chol), glucose, insulin,
Homeostasis Model Assessment (HOMA), plasma C-reactive protein (CRP) and
pentraxin-3 (PTX3) in ACS and Control groups. Results are reported as Mean ±
SD (Range) except for non-normally distributed HOMA-IR, CRP, PTX3, that are
presented as Median (Range). *:P < 0.05 between ACS and Control groups by
Wilcoxon test for non-normally distributed data (HOMA-IR, CRP, PTX3).
Barazzoni et al. Cardiovascular Diabetology 2013, 12:167 Page 3 of 7
http://www.cardiab.com/content/12/1/167associations between groups of statistically related vari-
ables. Due to non-normal distribution, log-transformed
values for PTX3, HOMA-IR and CRP were used for
regression analyses, and log-transformed PTX3 was used
as dependent variable in multiple regression analyses.
All data are reported as Mean ± Standard Deviation and
range, unless stated otherwise. P values of less than 0.05
were considered statistically significant.
Results
Clinical characteristics, metabolic and hormonal profile
ACS and non-ACS patients were comparable for sex,
age, BMI, waist circumference, prevalence of hyperten-
sion and dyslipidemia, type 2 diabetes, blood pressure,
lipid profile, plasma glucose and HOMA insulin resist-
ance index. Plasma C-reactive protein and PTX3 were
higher in the whole ACS group than in non-ACS
patients (Table 1).
Obesity, waist circumference and PTX3
Both non-obese and obese subjects with ACS had higher
PTX3 compared to matched control subjects (P < 0.05).
PTX3 was however lower in obese than in non-obese
individuals in both ACS (Non-Obese: 8.4 ± 0.9, Obese:
4.8 ± 0.1 nmol/ml, P = 0.02) and non-ACS group (Non-
Obese: 3.2 ± 0.1, Obese: 2.5 ± 0.1, P = 0.04) (Figure 1a).
Similarly, when subjects were divided into two groups
with high or normal waist circumference according to
ATP III classification (Males: WC > 102 cm, Females:
WC > 88 cm), PTX3 was lower in high- than in normal-
waist circumference individuals in both ACS (Normal
WC: 8.7 ± 1.1, High WC: 5.6 ± 0.24 nmol/ml, P = 0.046)
and non-ACS group (Normal WC: 3.3 ± 0.14, High WC:
2.6 ± 0.1 nmol/ml, P = 0.03) (Figure 1b).
Linear regression analysis between PTX3 and
anthropometric and biochemical variables in all ACS
subjects
In all ACS subjects (n = 72) PTX3 was associated posi-
tively with age and plasma creatinine. Consistent with
the impact of obesity and waist circumference on PTX3,
plasma PTX3 was associated negatively with BMI and
WC (Figure 2), and both associations were independent
of age and plasma creatinine in multiple regression ana-
lysis (Tables 2, 3). No statistically significant associations
were instead observed between PTX3 and total and
HDL-cholesterol, triglycerides, blood pressure, plasma
glucose, insulin and HOMA insulin resistance index
(Table 2), despite higher insulin and HOMA index in
obese compared to non-obese subjects in both ACS
and control groups (P < 0.05). Similar associations of
PTX3 were observed in the control group alone (BMI:
r = −0.32, P = 0.04, WC: r = −0.22, P = 0.08). When all
patients and control subjects were considered together,however, the correlations were no longer significant
(BMI: r = −0.15, P = 0.11, WC: r = −0.04, P > 0.2) likely
due to different PTX3 plasma concentrations in the two
groups at any given BMI level.
Obesity, waist circumference and CRP
At variance with plasma PTX3, CRP was not lower in
obese than in non-obese ACS patients (P > 0.2). Compar-
able CRP plasma concentrations were also observed
when patients were stratified according to waist circum-
ference (P > 0.2). Plasma CRP was accordingly not
Figure 1 a) Plasma PTX3 in non-obese and obese (BMI > 30 kg/m2) acute coronary syndrome patients (ACS; non-obese n = 49, obese
n = 23) and control subjects (non-ACS; non-obese n = 33, obese n = 19); b) Plasma PTX3 in patients with normal or high waist circum-
ference (WC) (> 102 or 88 cm for male and female subjects, respectively) in the acute coronary syndrome (ACS; normal WC n = 34, high
WC n = 38) and control groups (non-ACS; normal WC n = 23, high-WC n = 29). *: P < 0.05 Obese vs corresponding Non-Obese group;
$: P < 0.05 Obese and Non-Obese ACS vs corresponding Non-ACS group, by Kruskal-Wallis test.
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(P > 0.2, not shown) (Figure 3).
Discussion
In the current study we provide novel information on
the impact of obesity or waist circumference on plasma
PTX3 in ACS. Results demonstrate that: 1) ACS leads to
plasma PTX3 elevation in both non-obese and obese pa-
tients; 2) obesity is however associated with lower PTX3
in people with and without ACS; 3) lower PTX3 is also
observed in patients with normal compared to thoseFigure 2 Associations between plasma PTX3 and BMI (a) or WC (b) inwith high waist circumference, a marker of abdominal
fat accumulation.
PTX3 is a component of the pentraxin superfamily re-
portedly involved in the modulation of vascular inflam-
mation and damage [1,2]. Although the majority of
available studies indicate a negative impact of obesity on
plasma PTX3 in the general population and various
disease states [11-18], obesity is a strong risk factor for
cardiovascular events and PTX3 is commonly elevated
in ACS [7-10]. The current data confirm that ACS en-
hances circulating PTX3, but they further demonstrateACS patients (n = 72).
Table 2 Linear regression analysis between PTX3 as
dependent variable and age, plasma creatinine,
triglycerides, total and HDL-cholesterol, glucose, insulin,
HOMA index and plasma C-reactive protein (CRP) in all















Figure 3 Plasma CRP in ACS patients. Left: non-obese (n = 49)
and obese (n = 23) patients; right: normal WC (n = 34) or high WC
(n = 38) patients. No statistically significant differences were observed
by Kruskal-Wallis test.
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tends from non-ACS to ACS individuals. Lack of statisti-
cally significant associations indicates that changes in
plasma lipid profile, glucose metabolism or systemic in-
flammation were unlikely to contribute to lower PTX3
in obese ACS patients. Since abdominal adipose tissue is
a potential relevant source of PTX3 [20,21], the impact
of waist circumference on plasma PTX3 was also dir-
ectly investigated, and a negative association was also
observed in ACS between waist circumference and
PTX3. Low PTX3 production in abdominal adipose tis-
sue could therefore be, at least in part, paradoxically re-
sponsible for lower PTX3 plasma concentration in ACS
patients with high waist circumference. As an alternative
explanation, obesity and abdominal fat accumulation
could lower PTX3 production in other cell types
through yet unidentified signalling and mechanisms, that
should be investigated in future studies.Table 3 Multiple regression analyses between PTX3
(dependent variable) and variables associated with PTX3
in linear regression analysis: age, plasma creatinine, BMI
(independent variables), in all ACS patients (n = 72)*: P <
0.05; **: P < 0.01
PTX3




Similar results were observed when WC was used instead of BMI (not shown).
*:P < 0.05.Higher PTX3 is associated with negative outcome in
ACS, and the current results therefore suggest that less
pronounced PTX3 elevation may contribute to positively
modulate outcome and survival in obese ACS patients
[7-10]. The association between PTX3 and negative
outcome had been originally proposed to involve direct
negative effects of PTX3 in cardiac and vascular tissues
[7]. Strong emerging evidence however indicates that
PTX3 elevation may represent an adaptive, anti-
inflammatory response to pre-existing vascular damage
[23,24], and this concept is also supported by differential
changes of pro-inflammatory short pentraxin CRP and
PTX3 in ACS in the current study. More pronounced
tissue damage, rather than PTX3 elevation per se, could
therefore be directly responsible for negative outcome
in ACS patients with highest PTX3. Potential BMI-
dependent characteristics of cardiovascular lesions
should be directly investigated in obese ACS patients,
along with their potential impact on PTX3.
Limitations of the present study should be acknowl-
edged. First, factors regulating PTX3 production and
plasma concentration remain largely unknown, and the
current cross-sectional study design in vivo could not
directly address potential mechanisms underlying altered
circulating PTX3, that should be investigated in experi-
mental models. The potential interaction between obes-
ity, PTX3 and ACS outcome and survival will also need
to be investigated and confirmed in future studies.
Finally, we selected to base the diagnosis of diabetes on
HbA1c levels, since plasma glucose could have been
acutely affected by metabolic changes induced ACS per
se. The current findings however indicate a novel link
between obesity and plasma PTX3 in ACS, and under-
standing the underlying mechanisms will likely lead to
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improve ACS prognosis in both obese and non-obese
patients.
Conclusion
In conclusion, we demonstrated a negative impact of
obesity on circulating PTX3 in ACS patients. A similar
negative impact was also observed for elevated waist
circumference, a surrogate marker of abdominal fat
accumulation. These effects do not extend to the
short pentraxin and validated inflammation marker CRP,
whose plasma concentrations were not reduced in obese
ACS patients. Low PTX3 is a novel potential modulator
of tissue damage and outcome in obese ACS patients.
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